Sage Therapeutics shares are trading higher after Stifel reiterated a Buy rating and said they expect SAGE-217 to show signs of efficacy in bipolar depression. Analysts said the upcoming July pipeline update may represent an 'incremental positive.'
Benzinga Newsdesk